- Home
- CVM vs ANL Comparison
CVM vs ANL Comparison
Compare CVM & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CVM | ANL |
|---|---|---|
| Founded | 1983 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.1M | 52.0M |
| IPO Year | 1987 | 2023 |
Fundamental Metrics
Financial Performance| Metric | CVM | ANL |
|---|---|---|
| Price | $4.98 | $1.42 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 63.5K | 31.4K |
| Earning Date | 01-12-2026 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.98 | $0.88 |
| 52 Week High | $32.70 | $2.99 |
Technical Indicators
Market Signals| Indicator | CVM | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 29.48 | 49.96 |
| Support Level | $6.20 | $1.42 |
| Resistance Level | $6.75 | $1.70 |
| Average True Range (ATR) | 0.52 | 0.18 |
| MACD | -0.09 | 0.04 |
| Stochastic Oscillator | 7.78 | 65.39 |
Price Performance
Historical ComparisonAbout CVM Cel-Sci Corporation
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.